Literature DB >> 22130963

Alteration of bone sialoprotein expression in osseous metastasized renal cell carcinomas and the tumor surrounding tissue.

F Mittag1, J Hennenlotter, L Minkley, I Ipach, D Schilling, M Scharpf, A Stenzl, U Leichtle, T Kluba.   

Abstract

Bone sialoprotein (BSP) regulates bone metabolism by directly influencing the activity of osteoblasts and osteoclasts. A significant correlation between the tissue expression of BSP in tumors and the occurrence of bone metastases was found in different cancers. Aim of this study was to identify the BSP expression in renal cell carcinomas (RCC) according to their stage of metastatic disease. Tissue samples of patients with RCC who underwent partial resection or nephrectomy were separated into three groups, each with 10 patients showing either no metastases (group I), only soft tissue metastases (group II) or bone metastases (group III) at date of surgery. Immunohistochemical analysis of BSP expression in tumor tissue and corresponding renal parenchyma was performed and evaluated with an established semiquantitative scoring system. BSP expression was detected both in tumor tissue and renal parenchyma. Concerning the expression in malignant tissue, no significant difference could be found between the three groups whereas the corresponding renal parenchyma showed a staining score of 164, 198 and 224 for group I, II and III (P = 0.07). RCC staged T3 showed only a little higher BSP expression than those staged T1/2 (P < 0.21), while the corresponding parenchyma of T3 tumors showed significantly higher expressions (P = 0.02). This pilot study revealed a correlation between expression of BSP and tumor staging and type of metastases, especially for osseous metastases in RCC. Alternation of BSP expression could be detected particularly in renal parenchyma and linked to the type of metastases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22130963     DOI: 10.1007/s10585-011-9441-5

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  21 in total

1.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.

Authors:  N S Fedarko; A Jain; A Karadag; M R Van Eman; L W Fisher
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

Review 2.  Integrin-mediated signaling in the regulation of osteoclast adhesion and activation.

Authors:  L T Duong; G A Rodan
Journal:  Front Biosci       Date:  1998-08-01

3.  Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs).

Authors:  Kalu U E Ogbureke; Larry W Fisher
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

Review 4.  Bone sialoprotein.

Authors:  B Ganss; R H Kim; J Sodek
Journal:  Crit Rev Oral Biol Med       Date:  1999

5.  Expression of bone sialoprotein in human lung cancer.

Authors:  A Bellahcène; N Maloujahmoum; L W Fisher; H Pastorino; E Tagliabue; S Ménard; V Castronovo
Journal:  Calcif Tissue Int       Date:  1997-09       Impact factor: 4.333

6.  Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption.

Authors:  F P Ross; J Chappel; J I Alvarez; D Sander; W T Butler; M C Farach-Carson; K A Mintz; P G Robey; S L Teitelbaum; D A Cheresh
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

7.  Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients.

Authors:  Ling-Chun Chen; Chun-Yi Hao; Yanek S Y Chiu; Patrick Wong; Jane S Melnick; Martin Brotman; John Moretto; Fredrick Mendes; Andrew P Smith; James L Bennington; Dan Moore; Nancy M Lee
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

8.  Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption.

Authors:  H I Roach
Journal:  Cell Biol Int       Date:  1994-06       Impact factor: 3.612

9.  Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer.

Authors:  D Waltregny; A Bellahcène; I Van Riet; L W Fisher; M Young; P Fernandez; W Dewé; J de Leval; V Castronovo
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

10.  Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.

Authors:  Gabriele Carlinfante; Daphne Vassiliou; Olle Svensson; Mikael Wendel; Dick Heinegård; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.